The Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia: Mechanism, Clinical Evidence, and Emerging Role in First-Line Interventional Therapy

To evaluate the current evidence base for the Zenflow Spring System, a novel minimally invasive therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia, and to define its potential role within evolving treatment paradigms. Clinical evaluation has progressed from early feasibility studies to multicenter pilot programs and a randomized sham-controlled pivotal trial. Across studies, Zenflow demonstrates improvements in symptom burden, quality of life, and urinary flow. Safety profiles are favorable, with low rates of serious adverse events and prolonged postoperative catheterization. Importantly, sexual function appears preserved, and objective cystoscopic data support long-term implant stability. The Zenflow Spring System represents a non-ablative, retrievable approach to prostatic urethral decompression with encouraging early and mid-term outcomes. Its outpatient feasibility, safety profile, and preservation of sexual function position it as a potential first-line interventional option. Ongoing studies will further define long-term durability and comparative effectiveness.